Avsola

E242411

Avsola is a biosimilar monoclonal antibody to infliximab used to treat various autoimmune inflammatory conditions.

All labels observed (1)

Label Occurrences
Avsola canonical 2

How this entity was disambiguated

Statements (47)

Predicate Object
instanceOf biologic medicinal product
biosimilar medicine
monoclonal antibody
tumor necrosis factor inhibitor
hasAdverseEffect infusion-related reaction
malignancy risk
reactivation of latent tuberculosis
serious infections
hasATCClass L04AB02
hasBlackBoxWarning malignancy
serious infections
hasBrandName Avsola self-link
hasContraindication active tuberculosis
severe infections
hasDosageForm concentrate for solution for infusion
solution for infusion
hasEffect reduces inflammation
suppresses immune response
hasIndication active ankylosing spondylitis
active psoriatic arthritis
fistulizing Crohn's disease
moderate to severe Crohn's disease
moderate to severe plaque psoriasis
moderate to severe rheumatoid arthritis
moderate to severe ulcerative colitis
hasInternationalNonproprietaryName infliximab-axxq
hasManufacturer Amgen
hasMechanismOfAction binds to soluble TNF-alpha
binds to transmembrane TNF-alpha
neutralizes TNF-alpha biological activity
hasOriginatorReferenceProduct Remicade
hasRegulatoryStatus approved in the European Union
approved in the United States
hasRouteOfAdministration intravenous infusion
isAdministeredBy healthcare professional
isAdministeredWith intravenous infusion equipment
isBiosimilarTo Remicade
surface form: infliximab
isUsedFor Crohn's disease
ankylosing spondylitis
plaque psoriasis
psoriatic arthritis
rheumatoid arthritis
ulcerative colitis
requiresMonitoring hepatitis B virus reactivation
signs and symptoms of infection
tuberculosis status
targets tumor necrosis factor alpha

How these facts were elicited

Referenced by (2)

Full triples — surface form annotated when it differs from this entity's canonical label.

Remicade hasBiosimilar Avsola
Avsola hasBrandName Avsola self-link